Aetna modified CPB 0491 covering coronary artery brachytherapy and adjunctive coronary interventions, effective February 25, 2026. Here's what billing teams need to know.
Aetna, a CVS Health company, updated CPB 0491 to define when coronary artery brachytherapy, abciximab (ReoPro), and intravascular shockwave lithotripsy are — and aren't — covered. The Aetna coronary artery brachytherapy coverage policy draws a hard line: CPT add-on code +92974 and HCPCS codes C7533 and Q3001 can clear claims under specific conditions, but CPT 92972 and HCPCS C1761 for coronary lithotripsy are flat-out excluded. If your team bills for any of these procedures in 2026, this policy directly controls your reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Coronary Artery Brachytherapy and Other Adjuncts to Coronary Interventions |
| Policy Code | CPB 0491 Aetna |
| Change Type | Modified |
| Effective Date | February 25, 2026 |
| Impact Level | High — exclusions carry significant claim denial risk for interventional cardiology and EP teams |
| Specialties Affected | Interventional cardiology, cardiovascular surgery, hospital outpatient billing |
| Key Action | Audit claims for CPT 92972 and HCPCS C1761 (lithotripsy) and remove from charge capture for Aetna patients immediately |
Aetna Coronary Artery Brachytherapy Coverage Criteria and Medical Necessity Requirements 2026
Aetna's coverage policy on CPB 0491 is narrow by design. Medical necessity is established for exactly two interventions.
First, coronary artery brachytherapy (intra-coronary radiation) is covered as an adjunct during a second angioplasty or stent placement. The blockage must have recurred inside a previously placed bare metal stent — that's in-stent restenosis. It applies to both native coronary arteries and coronary artery bypass grafts. Bill this using CPT add-on code +92974, HCPCS C7533, and Q3001 for the radioelements.
Second, abciximab (ReoPro), billed under HCPCS J0130, is medically necessary as adjunctive treatment for patients undergoing percutaneous angioplasty or stent placement. That's the covered use. Everything else is off the table — and the list of excluded indications is long.
Whether Aetna requires prior authorization for these procedures isn't specified in CPB 0491 directly. Check the member's specific plan benefits before billing. Prior auth requirements vary by plan, and a missed prior auth is the easiest claim denial to avoid.
Aetna Coronary Artery Brachytherapy Exclusions and Non-Covered Indications
This is where most billing errors will happen. Aetna classifies four broad categories as experimental, investigational, or unproven under CPB 0491.
Coronary artery brachytherapy beyond in-stent restenosis. If your physician is using brachytherapy with drug-eluting stents — not bare metal stents — Aetna won't cover it. Primary prevention of restenosis is also excluded. Only bare metal stent in-stent restenosis qualifies for coverage.
Abciximab (J0130) for off-label indications. The policy lists eight specific non-covered uses. These include acute ischemic stroke, acute limb ischemia, AMI without percutaneous intervention, Kawasaki disease coronary complications, saphenous vein graft interventions, superficial femoral occlusive disease stenting, thromboembolic complications during cerebral aneurysm coiling, and thrombus resolution during intracranial bypass surgery. Billing J0130 against any of these diagnoses — including ICD-10 codes in ranges I63.00–I66.9 for cerebral artery occlusion, I74.3 for lower extremity thrombosis, or M30.3 for Kawasaki disease — will generate a denial.
Abciximab/heparin for LVAD implantation with HIT. CPT 33979 for ventricular assist device implantation combined with J0130 in patients with heparin-induced thrombocytopenia (ICD-10 D75.821–D75.829) is explicitly excluded. This is a narrow but high-stakes exclusion. If your team manages LVAD patients with HIT, flag this with your compliance officer before billing.
Intravascular shockwave lithotripsy. CPT 92972 and HCPCS C1761 are not covered for coronary artery plaques. Full stop. Shockwave lithotripsy has FDA clearance and growing clinical adoption, but Aetna has not moved this to covered status. Don't bill these codes expecting reimbursement from Aetna.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| In-stent restenosis (bare metal stent), brachytherapy during second angioplasty/stent | Covered | +92974, C7533, Q3001 | Native coronary arteries and bypass grafts both eligible |
| Abciximab as adjunct during percutaneous angioplasty/stent placement | Covered | J0130 | Must be adjunctive to PCI |
| Brachytherapy with drug-eluting stents | Not Covered | +92974 | Insufficient evidence; excluded under CPB 0491 |
| Brachytherapy for primary restenosis prevention | Not Covered | +92974 | All indications except bare metal in-stent restenosis excluded |
| Abciximab for acute ischemic stroke | Not Covered | J0130 | ICD-10 I63.00–I66.9; no RCT evidence |
| Abciximab for acute limb ischemia | Not Covered | J0130 | ICD-10 I74.3, I99.9 |
| Abciximab for AMI without PCI | Not Covered | J0130 | Explicitly excluded |
| Abciximab for Kawasaki disease (coronary aneurysms) | Not Covered | J0130 | ICD-10 M30.3, I25.41 |
| Abciximab for saphenous vein graft interventions | Not Covered | J0130 | See T82.211A–T82.218S |
| Abciximab for superficial femoral occlusive disease stenting | Not Covered | J0130 | Not separately listed in ICD-10 table |
| Abciximab for cerebral aneurysm coiling complications | Not Covered | J0130 | ICD-10 I63.00–I66.9 range |
| Abciximab for intracranial bypass thrombus resolution | Not Covered | J0130 | CPT 61624 also not covered for these indications |
| Abciximab/heparin for LVAD implantation with HIT | Not Covered | J0130, CPT 33979 | ICD-10 D75.821–D75.829 |
| Intravascular shockwave lithotripsy for coronary plaques | Not Covered | 92972, C1761 | Experimental/investigational per CPB 0491 |
Aetna Coronary Artery Brachytherapy Billing Guidelines and Action Items 2026
The effective date is February 25, 2026. If you haven't already audited your charge capture for these codes, do it now.
| # | Action Item |
|---|---|
| 1 | Remove CPT 92972 and HCPCS C1761 from Aetna charge capture immediately. Coronary lithotripsy is not covered under this coverage policy. Any claim with these codes against an Aetna plan will deny. If your interventional cath lab has been billing these, run a 90-day lookback and identify any claims that went out after February 25, 2026. |
| 2 | Verify the stent type before billing +92974, C7533, or Q3001. The medical necessity threshold is a bare metal stent with confirmed in-stent restenosis. Document the original stent type in the procedure note. If the prior stent was drug-eluting, brachytherapy billing guidelines do not support coverage under CPB 0491 — and Aetna will deny on clinical review. |
| 3 | Audit J0130 (abciximab) claims for diagnosis code alignment. Cross-reference every abciximab claim against the excluded ICD-10 codes. If you're billing J0130 with I63.00–I66.9, I74.3, I99.9, M30.3, or D75.821–D75.829, those claims will deny. Update your billing system to flag these code combinations before claims go out. |
| 4 | Flag LVAD cases with HIT before billing. CPT 33979 combined with J0130 in any patient carrying a heparin-induced thrombocytopenia diagnosis (D75.821–D75.829) is explicitly excluded. Loop in your compliance officer if this combination appears in your patient mix. The clinical complexity here creates documentation risk beyond the billing issue. |
| 5 | Check prior authorization requirements at the plan level. CPB 0491 establishes medical necessity standards but doesn't publish a universal prior auth list. Aetna plan benefits vary. Before scheduling brachytherapy or billing abciximab adjunct claims, confirm whether that specific member's plan requires prior authorization for CPT +92974 or J0130. |
| 6 | Educate your interventional cardiology coders on the drug-eluting stent distinction. This is the most likely source of inadvertent upcoding. A coder seeing "brachytherapy + stent placement" may not know the bare metal vs. drug-eluting distinction matters for coverage. Build it into your coding guidelines and coder training before the next billing cycle. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Coronary Artery Brachytherapy Under CPB 0491
Covered CPT and HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| +92974 | CPT (add-on) | Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy |
| C7533 | HCPCS | Percutaneous transluminal coronary angioplasty, single major coronary artery or branch with transcatheter placement of radiation delivery device |
| J0130 | HCPCS | Injection abciximab, 10 mg (except for AMI without percutaneous intervention) |
| Q3001 | HCPCS | Radioelements for brachytherapy, any type, each |
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 92972 | CPT | Percutaneous transluminal coronary lithotripsy (add-on) | Experimental/investigational — not covered for coronary artery plaques |
| 61624 | CPT | Transcatheter occlusion or embolization | Not covered for indications listed in CPB 0491 |
| C1761 | HCPCS | Catheter, transluminal intravascular lithotripsy, coronary | Not covered — corresponds to excluded CPT 92972 |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D75.821–D75.829 | Heparin-induced thrombocytopenia (multiple specificity levels) |
| I20.0–I25.3 | Ischemic heart diseases |
| I25.41 | Coronary artery aneurysm |
| I25.42–I25.9 | Ischemic heart diseases (continued range) |
| I63.00–I66.9 | Occlusion and stenosis of cerebral and precerebral arteries |
| I74.3 | Embolism and thrombosis of arteries of the lower extremities |
| I99.9 | Unspecified disorder of circulatory system (acute limb ischemia) |
| M30.3 | Mucocutaneous lymph node syndrome (Kawasaki disease) |
| T82.211A–T82.218S | Mechanical complication due to coronary bypass graft |
| T82.817A–T82.817S | Other specified complications of other cardiac devices, implants and grafts |
| T82.827A–T82.827S, T82.837A–T82.837S | Other specified complications of other cardiac devices, implants and grafts |
| T82.847A–T82.847S, T82.857A–T82.857S | Other specified complications of other cardiac devices, implants and grafts |
| T82.867A–T82.867S, T82.897A–T82.897S | Other specified complications of other cardiac devices, implants and grafts |
| T82.9xxA–T82.9XXS | Other specified complications of other cardiac devices, implants and grafts |
| Z95.1 | Presence of aortocoronary bypass graft |
| Z95.5 | Presence of coronary angioplasty implant and graft |
| Z98.61 | Coronary angioplasty status |
Get the Full Picture for CPT 92972
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.